

Global Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030

<https://marketpublishers.com/r/GC20A48B51A6EN.html>

Date: April 2024

Pages: 197

Price: US\$ 3,950.00 (Single User License)

ID: GC20A48B51A6EN

Abstracts

Summary

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

According to APO Research, The global Biologics and Biosimilars market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Biologics and Biosimilars is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Biologics and Biosimilars is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Biologics and Biosimilars is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Biologics and Biosimilars is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Biologics and Biosimilars segment by Company

Roche

Amgen

AbbVie

Sanofi-Aventis

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

3sbio

Changchun High Tech

CP Guojian

Biotech

Gelgen

Innovent

Dong Bao

Ganlee

United Laboratories

Biologics and Biosimilars segment by Type

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

Biologics and Biosimilars segment by Application

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

Biologics and Biosimilars segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biologics and Biosimilars in regional level. It provides a quantitative

analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Global Biologics and Biosimilars Market Size, 2019 VS 2023 VS 2030
- 1.3 Global Biologics and Biosimilars Market Size Estimates and Forecasts (2019-2030)
- 1.4 Global Biologics and Biosimilars Sales Estimates and Forecasts (2019-2030)
- 1.5 Global Biologics and Biosimilars Market Average Price (2019-2030)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives

2 GLOBAL BIOLOGICS AND BIOSIMILARS MARKET DYNAMICS

- 2.1 Biologics and Biosimilars Industry Trends
- 2.2 Biologics and Biosimilars Industry Drivers
- 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
- 2.4 Biologics and Biosimilars Industry Restraints

3 BIOLOGICS AND BIOSIMILARS MARKET BY MANUFACTURERS

- 3.1 Global Biologics and Biosimilars Revenue by Manufacturers (2019-2024)
- 3.2 Global Biologics and Biosimilars Sales by Manufacturers (2019-2024)
- 3.3 Global Biologics and Biosimilars Average Sales Price by Manufacturers (2019-2024)
- 3.4 Global Biologics and Biosimilars Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
- 3.5 Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Biologics and Biosimilars Manufacturers, Product Type & Application
- 3.7 Global Biologics and Biosimilars Manufacturers Commercialization Time
- 3.8 Market Competitive Analysis
 - 3.8.1 Global Biologics and Biosimilars Market CR5 and HHI
 - 3.8.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
 - 3.8.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier

4 BIOLOGICS AND BIOSIMILARS MARKET BY TYPE

- 4.1 Biologics and Biosimilars Type Introduction

- 4.1.1 Monoclonal Antibodies
- 4.1.2 Interferon
- 4.1.3 Erythropoietin
- 4.1.4 Insulin
- 4.1.5 Vaccines
- 4.1.6 Others
- 4.2 Global Biologics and Biosimilars Sales by Type
 - 4.2.1 Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030)
 - 4.2.2 Global Biologics and Biosimilars Sales by Type (2019-2030)
 - 4.2.3 Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
- 4.3 Global Biologics and Biosimilars Revenue by Type
 - 4.3.1 Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030)
 - 4.3.2 Global Biologics and Biosimilars Revenue by Type (2019-2030)
 - 4.3.3 Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)

5 BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION

- 5.1 Biologics and Biosimilars Application Introduction
 - 5.1.1 Tumor
 - 5.1.2 Diabetes
 - 5.1.3 Cardiovascular
 - 5.1.4 Hemophilia
 - 5.1.5 Others
- 5.2 Global Biologics and Biosimilars Sales by Application
 - 5.2.1 Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030)
 - 5.2.2 Global Biologics and Biosimilars Sales by Application (2019-2030)
 - 5.2.3 Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
- 5.3 Global Biologics and Biosimilars Revenue by Application
 - 5.3.1 Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030)
 - 5.3.2 Global Biologics and Biosimilars Revenue by Application (2019-2030)
 - 5.3.3 Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)

6 GLOBAL BIOLOGICS AND BIOSIMILARS SALES BY REGION

- 6.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
- 6.2 Global Biologics and Biosimilars Sales by Region (2019-2030)
 - 6.2.1 Global Biologics and Biosimilars Sales by Region (2019-2024)

6.2.2 Global Biologics and Biosimilars Sales Forecasted by Region (2025-2030)

6.3 North America

6.3.1 North America Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030

6.3.2 North America Biologics and Biosimilars Sales by Country (2019-2030)

6.3.3 U.S.

6.3.4 Canada

6.4 Europe

6.4.1 Europe Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030

6.4.2 Europe Biologics and Biosimilars Sales by Country (2019-2030)

6.4.3 Germany

6.4.4 France

6.4.5 U.K.

6.4.6 Italy

6.4.7 Netherlands

6.5 Asia Pacific

6.5.1 Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030

6.5.2 Asia Pacific Biologics and Biosimilars Sales by Country (2019-2030)

6.5.3 China

6.5.4 Japan

6.5.5 South Korea

6.5.6 Southeast Asia

6.5.7 India

6.5.8 Australia

6.6 LAMEA

6.6.1 LAMEA Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030

6.6.2 LAMEA Biologics and Biosimilars Sales by Country (2019-2030)

6.6.3 Mexico

6.6.4 Brazil

6.6.5 Turkey

6.6.6 GCC Countries

7 GLOBAL BIOLOGICS AND BIOSIMILARS REVENUE BY REGION

7.1 Global Biologics and Biosimilars Revenue by Region

7.1.1 Global Biologics and Biosimilars Revenue by Region: 2019 VS 2023 VS 2030

- 7.1.2 Global Biologics and Biosimilars Revenue by Region (2019-2024)
- 7.1.3 Global Biologics and Biosimilars Revenue by Region (2025-2030)
- 7.1.4 Global Biologics and Biosimilars Revenue Market Share by Region (2019-2030)
- 7.2 North America
 - 7.2.1 North America Biologics and Biosimilars Revenue (2019-2030)
 - 7.2.2 North America Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
- 7.3 Europe
 - 7.3.1 Europe Biologics and Biosimilars Revenue (2019-2030)
 - 7.3.2 Europe Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
- 7.4 Asia-Pacific
 - 7.4.1 Asia-Pacific Biologics and Biosimilars Revenue (2019-2030)
 - 7.4.2 Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
- 7.5 LAMEA
 - 7.5.1 LAMEA Biologics and Biosimilars Revenue (2019-2030)
 - 7.5.2 LAMEA Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030

8 COMPANY PROFILES

- 8.1 Roche
 - 8.1.1 Roche Company Information
 - 8.1.2 Roche Business Overview
 - 8.1.3 Roche Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
 - 8.1.4 Roche Biologics and Biosimilars Product Portfolio
 - 8.1.5 Roche Recent Developments
- 8.2 Amgen
 - 8.2.1 Amgen Company Information
 - 8.2.2 Amgen Business Overview
 - 8.2.3 Amgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
 - 8.2.4 Amgen Biologics and Biosimilars Product Portfolio
 - 8.2.5 Amgen Recent Developments
- 8.3 AbbVie
 - 8.3.1 AbbVie Company Information
 - 8.3.2 AbbVie Business Overview

8.3.3 AbbVie Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)

8.3.4 AbbVie Biologics and Biosimilars Product Portfolio

8.3.5 AbbVie Recent Developments

8.4 Sanofi-Aventis

8.4.1 Sanofi-Aventis Company Information

8.4.2 Sanofi-Aventis Business Overview

8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)

8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio

8.4.5 Sanofi-Aventis Recent Developments

8.5 Johnson & Johnson

8.5.1 Johnson & Johnson Company Information

8.5.2 Johnson & Johnson Business Overview

8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)

8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio

8.5.5 Johnson & Johnson Recent Developments

8.6 Pfizer

8.6.1 Pfizer Company Information

8.6.2 Pfizer Business Overview

8.6.3 Pfizer Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)

8.6.4 Pfizer Biologics and Biosimilars Product Portfolio

8.6.5 Pfizer Recent Developments

8.7 Novo Nordisk

8.7.1 Novo Nordisk Company Information

8.7.2 Novo Nordisk Business Overview

8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)

8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio

8.7.5 Novo Nordisk Recent Developments

8.8 Eli Lilly

8.8.1 Eli Lilly Company Information

8.8.2 Eli Lilly Business Overview

8.8.3 Eli Lilly Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)

8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio

8.8.5 Eli Lilly Recent Developments

8.9 Novartis

8.9.1 Novartis Company Information

8.9.2 Novartis Business Overview

8.9.3 Novartis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin
(2019-2024)

8.9.4 Novartis Biologics and Biosimilars Product Portfolio

8.9.5 Novartis Recent Developments

8.10 Merck

8.10.1 Merck Company Information

8.10.2 Merck Business Overview

8.10.3 Merck Biologics and Biosimilars Sales, Price, Revenue and Gross Margin
(2019-2024)

8.10.4 Merck Biologics and Biosimilars Product Portfolio

8.10.5 Merck Recent Developments

8.11 3sbio

8.11.1 3sbio Company Information

8.11.2 3sbio Business Overview

8.11.3 3sbio Biologics and Biosimilars Sales, Price, Revenue and Gross Margin
(2019-2024)

8.11.4 3sbio Biologics and Biosimilars Product Portfolio

8.11.5 3sbio Recent Developments

8.12 Changchun High Tech

8.12.1 Changchun High Tech Company Information

8.12.2 Changchun High Tech Business Overview

8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Price, Revenue and
Gross Margin (2019-2024)

8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio

8.12.5 Changchun High Tech Recent Developments

8.13 CP Guojian

8.13.1 CP Guojian Company Information

8.13.2 CP Guojian Business Overview

8.13.3 CP Guojian Biologics and Biosimilars Sales, Price, Revenue and Gross Margin
(2019-2024)

8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio

8.13.5 CP Guojian Recent Developments

8.14 Biotech

8.14.1 Biotech Company Information

8.14.2 Biotech Business Overview

8.14.3 Biotech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin

(2019-2024)

8.14.4 Biotech Biologics and Biosimilars Product Portfolio

8.14.5 Biotech Recent Developments

8.15 Gelgen

8.15.1 Gelgen Company Information

8.15.2 Gelgen Business Overview

8.15.3 Gelgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin

(2019-2024)

8.15.4 Gelgen Biologics and Biosimilars Product Portfolio

8.15.5 Gelgen Recent Developments

8.16 Innovent

8.16.1 Innovent Company Information

8.16.2 Innovent Business Overview

8.16.3 Innovent Biologics and Biosimilars Sales, Price, Revenue and Gross Margin

(2019-2024)

8.16.4 Innovent Biologics and Biosimilars Product Portfolio

8.16.5 Innovent Recent Developments

8.17 Dong Bao

8.17.1 Dong Bao Company Information

8.17.2 Dong Bao Business Overview

8.17.3 Dong Bao Biologics and Biosimilars Sales, Price, Revenue and Gross Margin

(2019-2024)

8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio

8.17.5 Dong Bao Recent Developments

8.18 Ganlee

8.18.1 Ganlee Company Information

8.18.2 Ganlee Business Overview

8.18.3 Ganlee Biologics and Biosimilars Sales, Price, Revenue and Gross Margin

(2019-2024)

8.18.4 Ganlee Biologics and Biosimilars Product Portfolio

8.18.5 Ganlee Recent Developments

8.19 United Laboratories

8.19.1 United Laboratories Company Information

8.19.2 United Laboratories Business Overview

8.19.3 United Laboratories Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)

8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio

8.19.5 United Laboratories Recent Developments

9 VALUE CHAIN AND SALES CHANNELS ANALYSIS

9.1 Biologics and Biosimilars Value Chain Analysis

9.1.1 Biologics and Biosimilars Key Raw Materials

9.1.2 Raw Materials Key Suppliers

9.1.3 Manufacturing Cost Structure

9.1.4 Biologics and Biosimilars Production Mode & Process

9.2 Biologics and Biosimilars Sales Channels Analysis

9.2.1 Direct Comparison with Distribution Share

9.2.2 Biologics and Biosimilars Distributors

9.2.3 Biologics and Biosimilars Customers

10 CONCLUDING INSIGHTS

11 APPENDIX

11.1 Reasons for Doing This Study

11.2 Research Methodology

11.3 Research Process

11.4 Authors List of This Report

11.5 Data Source

11.5.1 Secondary Sources

11.5.2 Primary Sources

11.6 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Biologics and Biosimilars Industry Trends
- Table 2. Biologics and Biosimilars Industry Drivers
- Table 3. Biologics and Biosimilars Industry Opportunities and Challenges
- Table 4. Biologics and Biosimilars Industry Restraints
- Table 5. Global Biologics and Biosimilars Revenue by Manufacturers (US\$ Million) & (2019-2024)
- Table 6. Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2019-2024)
- Table 7. Global Biologics and Biosimilars Sales by Manufacturers (K Units) & (2019-2024)
- Table 8. Global Biologics and Biosimilars Sales Market Share by Manufacturers
- Table 9. Global Biologics and Biosimilars Average Sales Price (USD/Unit) of Manufacturers (2019-2024)
- Table 10. Global Biologics and Biosimilars Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
- Table 11. Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
- Table 12. Global Biologics and Biosimilars Manufacturers, Product Type & Application
- Table 13. Global Biologics and Biosimilars Manufacturers Commercialization Time
- Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 15. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
- Table 16. Major Manufacturers of Monoclonal Antibodies
- Table 17. Major Manufacturers of Interferon
- Table 18. Major Manufacturers of Erythropoietin
- Table 19. Major Manufacturers of Insulin
- Table 20. Major Manufacturers of Vaccines
- Table 21. Major Manufacturers of Others
- Table 22. Global Biologics and Biosimilars Sales by Type 2019 VS 2023 VS 2030 (K Units)
- Table 23. Global Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
- Table 24. Global Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
- Table 25. Global Biologics and Biosimilars Sales Market Share by Type (2019-2024)
- Table 26. Global Biologics and Biosimilars Sales Market Share by Type (2025-2030)
- Table 27. Global Biologics and Biosimilars Revenue by Type 2019 VS 2023 VS 2030 (K

Units)

Table 28. Global Biologics and Biosimilars Revenue by Type (2019-2024) & (K Units)

Table 29. Global Biologics and Biosimilars Revenue by Type (2025-2030) & (K Units)

Table 30. Global Biologics and Biosimilars Revenue Market Share by Type (2019-2024)

Table 31. Global Biologics and Biosimilars Revenue Market Share by Type (2025-2030)

Table 32. Major Manufacturers of Tumor

Table 33. Major Manufacturers of Diabetes

Table 34. Major Manufacturers of Cardiovascular

Table 35. Major Manufacturers of Hemophilia

Table 36. Major Manufacturers of Others

Table 37. Global Biologics and Biosimilars Sales by Application 2019 VS 2023 VS 2030 (K Units)

Table 38. Global Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)

Table 39. Global Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)

Table 40. Global Biologics and Biosimilars Sales Market Share by Application (2019-2024)

Table 41. Global Biologics and Biosimilars Sales Market Share by Application (2025-2030)

Table 42. Global Biologics and Biosimilars Revenue by Application 2019 VS 2023 VS 2030 (K Units)

Table 43. Global Biologics and Biosimilars Revenue by Application (2019-2024) & (K Units)

Table 44. Global Biologics and Biosimilars Revenue by Application (2025-2030) & (K Units)

Table 45. Global Biologics and Biosimilars Revenue Market Share by Application (2019-2024)

Table 46. Global Biologics and Biosimilars Revenue Market Share by Application (2025-2030)

Table 47. Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030 (K Units)

Table 48. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)

Table 49. Global Biologics and Biosimilars Sales Market Share by Region (2019-2024)

Table 50. Global Biologics and Biosimilars Sales Forecasted by Region (2025-2030) & (K Units)

Table 51. Global Biologics and Biosimilars Sales Forecasted Market Share by Region (2025-2030)

Table 52. North America Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)

Table 53. North America Biologics and Biosimilars Sales by Country (2019-2024) & (K

Units)

Table 54. North America Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)

Table 55. Europe Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)

Table 56. Europe Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)

Table 57. Europe Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)

Table 58. Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)

Table 59. Asia Pacific Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)

Table 60. Asia Pacific Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)

Table 61. LAMEA Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)

Table 62. LAMEA Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)

Table 63. LAMEA Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)

Table 64. Global Biologics and Biosimilars Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US\$ Million)

Table 65. Global Biologics and Biosimilars Revenue by Region (2019-2024) & (US\$ Million)

Table 66. Global Biologics and Biosimilars Revenue by Region (2025-2030) & (US\$ Million)

Table 67. Global Biologics and Biosimilars Revenue Market Share by Region (2019-2024)

Table 68. Global Biologics and Biosimilars Revenue Market Share by Region (2025-2030)

Table 69. Roche Company Information

Table 70. Roche Business Overview

Table 71. Roche Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 72. Roche Biologics and Biosimilars Product Portfolio

Table 73. Roche Recent Development

Table 74. Amgen Company Information

Table 75. Amgen Business Overview

Table 76. Amgen Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 77. Amgen Biologics and Biosimilars Product Portfolio

Table 78. Amgen Recent Development

Table 79. AbbVie Company Information

Table 80. AbbVie Business Overview

Table 81. AbbVie Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 82. AbbVie Biologics and Biosimilars Product Portfolio

Table 83. AbbVie Recent Development

Table 84. Sanofi-Aventis Company Information

Table 85. Sanofi-Aventis Business Overview

Table 86. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 87. Sanofi-Aventis Biologics and Biosimilars Product Portfolio

Table 88. Sanofi-Aventis Recent Development

Table 89. Johnson & Johnson Company Information

Table 90. Johnson & Johnson Business Overview

Table 91. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 92. Johnson & Johnson Biologics and Biosimilars Product Portfolio

Table 93. Johnson & Johnson Recent Development

Table 94. Pfizer Company Information

Table 95. Pfizer Business Overview

Table 96. Pfizer Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 97. Pfizer Biologics and Biosimilars Product Portfolio

Table 98. Pfizer Recent Development

Table 99. Novo Nordisk Company Information

Table 100. Novo Nordisk Business Overview

Table 101. Novo Nordisk Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 102. Novo Nordisk Biologics and Biosimilars Product Portfolio

Table 103. Novo Nordisk Recent Development

Table 104. Eli Lilly Company Information

Table 105. Eli Lilly Business Overview

Table 106. Eli Lilly Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 107. Eli Lilly Biologics and Biosimilars Product Portfolio

Table 108. Eli Lilly Recent Development

Table 109. Novartis Company Information

Table 110. Novartis Business Overview

Table 111. Novartis Biologics and Biosimilars Sales (K Units), Price (USD/Unit),

Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 112. Novartis Biologics and Biosimilars Product Portfolio

Table 113. Novartis Recent Development

Table 114. Merck Company Information

Table 115. Merck Business Overview

Table 116. Merck Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 117. Merck Biologics and Biosimilars Product Portfolio

Table 118. Merck Recent Development

Table 119. 3sbio Company Information

Table 120. 3sbio Business Overview

Table 121. 3sbio Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 122. 3sbio Biologics and Biosimilars Product Portfolio

Table 123. 3sbio Recent Development

Table 124. Changchun High Tech Company Information

Table 125. Changchun High Tech Business Overview

Table 126. Changchun High Tech Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 127. Changchun High Tech Biologics and Biosimilars Product Portfolio

Table 128. Changchun High Tech Recent Development

Table 129. CP Guojian Company Information

Table 130. CP Guojian Business Overview

Table 131. CP Guojian Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 132. CP Guojian Biologics and Biosimilars Product Portfolio

Table 133. CP Guojian Recent Development

Table 134. Biotech Company Information

Table 135. Biotech Business Overview

Table 136. Biotech Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 137. Biotech Biologics and Biosimilars Product Portfolio

Table 138. Biotech Recent Development

Table 139. Gelgen Company Information

Table 140. Gelgen Business Overview

Table 141. Gelgen Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 142. Gelgen Biologics and Biosimilars Product Portfolio

Table 143. Gelgen Recent Development

Table 144. Innovent Company Information

Table 145. Innovent Business Overview

Table 146. Innovent Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 147. Innovent Biologics and Biosimilars Product Portfolio

Table 148. Innovent Recent Development

Table 149. Dong Bao Company Information

Table 150. Dong Bao Business Overview

Table 151. Dong Bao Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 152. Dong Bao Biologics and Biosimilars Product Portfolio

Table 153. Dong Bao Recent Development

Table 154. Ganlee Company Information

Table 155. Ganlee Business Overview

Table 156. Ganlee Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 157. Ganlee Biologics and Biosimilars Product Portfolio

Table 158. Ganlee Recent Development

Table 159. United Laboratories Company Information

Table 160. United Laboratories Business Overview

Table 161. United Laboratories Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 162. United Laboratories Biologics and Biosimilars Product Portfolio

Table 163. United Laboratories Recent Development

Table 164. Key Raw Materials

Table 165. Raw Materials Key Suppliers

Table 166. Biologics and Biosimilars Distributors List

Table 167. Biologics and Biosimilars Customers List

Table 168. Research Programs/Design for This Report

Table 169. Authors List of This Report

Table 170. Secondary Sources

Table 171. Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Biologics and Biosimilars Product Picture
- Figure 2. Global Biologics and Biosimilars Market Size (US\$ Million), 2019 VS 2023 VS 2030
- Figure 3. Global Biologics and Biosimilars Market Size (2019-2030) & (US\$ Million)
- Figure 4. Global Biologics and Biosimilars Sales (2019-2030) & (K Units)
- Figure 5. Global Biologics and Biosimilars Average Price (USD/Unit) & (2019-2030)
- Figure 6. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
- Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
- Figure 8. Monoclonal Antibodies Picture
- Figure 9. Interferon Picture
- Figure 10. Erythropoietin Picture
- Figure 11. Insulin Picture
- Figure 12. Vaccines Picture
- Figure 13. Others Picture
- Figure 14. Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030) & (K Units)
- Figure 15. Global Biologics and Biosimilars Sales Market Share 2019 VS 2023 VS 2030
- Figure 16. Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
- Figure 17. Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030) & (K Units)
- Figure 18. Global Biologics and Biosimilars Revenue Market Share 2019 VS 2023 VS 2030
- Figure 19. Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
- Figure 20. Tumor Picture
- Figure 21. Diabetes Picture
- Figure 22. Cardiovascular Picture
- Figure 23. Hemophilia Picture
- Figure 24. Others Picture
- Figure 25. Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030) & (K Units)
- Figure 26. Global Biologics and Biosimilars Sales Market Share 2019 VS 2023 VS 2030
- Figure 27. Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)

Figure 28. Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 29. Global Biologics and Biosimilars Revenue Market Share 2019 VS 2023 VS 2030

Figure 30. Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)

Figure 31. North America Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 32. North America Biologics and Biosimilars Sales Market Share by Country (2019-2030)

Figure 33. U.S. Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 34. Canada Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 35. Europe Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 36. Europe Biologics and Biosimilars Sales Market Share by Country (2019-2030)

Figure 37. Germany Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 38. France Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 39. U.K. Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 40. Italy Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 41. Netherlands Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 42. Asia Pacific Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 43. Asia Pacific Biologics and Biosimilars Sales Market Share by Country (2019-2030)

Figure 44. China Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 45. Japan Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 46. South Korea Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 47. Southeast Asia Biologics and Biosimilars Sales and Growth Rate

(2019-2030) & (K Units)

Figure 48. India Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 49. Australia Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 50. LAMEA Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 51. LAMEA Biologics and Biosimilars Sales Market Share by Country (2019-2030)

Figure 52. Mexico Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 53. Brazil Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 54. Turkey Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 55. GCC Countries Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)

Figure 56. Global Biologics and Biosimilars Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US\$ Million)

Figure 57. Global Biologics and Biosimilars Revenue Market Share by Region in Percentage: 2023 Versus 2030

Figure 58. North America Biologics and Biosimilars Revenue (2019-2030) & (US\$ Million)

Figure 59. North America Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030

Figure 60. Europe Biologics and Biosimilars Revenue (2019-2030) & (US\$ Million)

Figure 61. Europe Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030

Figure 62. Asia-Pacific Biologics and Biosimilars Revenue (2019-2030) & (US\$ Million)

Figure 63. Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030

Figure 64. LAMEA Biologics and Biosimilars Revenue (2019-2030) & (US\$ Million)

Figure 65. LAMEA Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030

Figure 66. Biologics and Biosimilars Value Chain

Figure 67. Manufacturing Cost Structure

Figure 68. Biologics and Biosimilars Production Mode & Process

Figure 69. Direct Comparison with Distribution Share

Figure 70. Distributors Profiles

Figure 71. Years Considered

Figure 72. Research Process

Figure 73. Key Executives Interviewed

I would like to order

Product name: Global Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030

Product link: <https://marketpublishers.com/r/GC20A48B51A6EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC20A48B51A6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

